Edgar Engleman

Publications

• T-cell activation by antigen-loaded pH-sensitive hydrogel particles in vivo: the effect of particle size. Cohen JA, Beaudette TT, Tseng WW, Bachelder EM, Mende I, Engleman EG, Fréchet JM. Bioconjug Chem. 2009; 20 (1): 111-9
• Plasmacytoid dendritic cells take up opsonized antigen leading to CD4+ and CD8+ T cell activation in vivo. Björck P, Beilhack A, Herman EI, Negrin RS, Engleman EG. J Immunol. 2008; 181 (6): 3811-7
• Tolerance and chimerism after renal and hematopoietic-cell transplantation. Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, Hoppe RT, Lowsky R, Engleman EG, Strober S. N Engl J Med. 2008; 358 (4): 362-8
• Incorporation of CpG oligonucleotide ligand into protein-loaded particle vaccines promotes antigen-specific CD8 T-cell immunity. Standley SM, Mende I, Goh SL, Kwon YJ, Beaudette TT, Engleman EG, Fréchet JM. Bioconjug Chem. 2007 Jan-Feb; 18 (1): 77-83
• Natural killer cells trigger differentiation of monocytes into dendritic cells. Zhang AL, Colmenero P, Purath U, Teixeira de Matos C, Hueber W, Klareskog L, Tarner IH, Engleman EG, Söderström K. Blood. 2007; 110 (7): 2484-93
• Orthotopic mouse model of colorectal cancer. Tseng W, Leong X, Engleman E. J Vis Exp. 2007; (10): 484
• Qa-1(b)-dependent modulation of dendritic cell and NK cell cross-talk in vivo. Colmenero P, Zhang AL, Qian T, Lu L, Cantor H, Söderström K, Engleman EG. J Immunol. 2007; 179 (7): 4608-15
• Flk2+ myeloid progenitors are the main source of Langerhans cells. Mende I, Karsunky H, Weissman IL, Engleman EG, Merad M. Blood. 2006; 107 (4): 1383-90
• Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy. Saji H, Song W, Furumoto K, Kato H, Engleman EG. Clin Cancer Res. 2006; 12 (8): 2568-74
• In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity. Okano F, Merad M, Furumoto K, Engleman EG. J Immunol. 2005; 174 (5): 2645-52
• Developmental origin of interferon-alpha-producing dendritic cells from hematopoietic precursors. Karsunky H, Merad M, Mende I, Manz MG, Engleman EG, Weissman IL. Exp Hematol. 2005; 33 (2): 173-81
• Breaking tolerance to tumors with dendritic cell-based immunotherapy. Mende I, Engleman EG. Ann N Y Acad Sci. 2005: 1058 96-104
• Using signaling pathways to overcome immune tolerance to tumors. Engleman EG, Brody J, Soares L. Sci STKE. 2004; 2004 (241): pe28
• DC-based cancer vaccines: lessons from clinical trials. Brody JD, Engleman EG. Cytotherapy. 2004; 6 (2): 122-7
• Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Merad M, Hoffmann P, Ranheim E, Slaymaker S, Manz MG, Lira SA, Charo I, Cook DN, Weissman IL, Strober S, Engleman EG. Nat Med. 2004; 10 (5): 510-7
• Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. Furumoto K, Soares L, Engleman EG, Merad M. J Clin Invest. 2004; 113 (5): 774-83
• Two isoforms of otubain 1 regulate T cell anergy via GRAIL. Soares L, Seroogy C, Skrenta H, Anandasabapathy N, Lovelace P, Chung CD, Engleman E, Fathman CG. Nat Immunol. 2004; 5 (1): 45-54
• Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patients. Engleman EG, Fong L. Clin Immunol. 2003; 106 (1): 10-5
• Dendritic cell-based cancer immunotherapy. Engleman EG, Semin Oncol. 2003; 30 (3 Suppl 8): 23-9
• Langerhans cells renew in the skin throughout life under steady-state conditions. Merad M, Manz MG, Karsunky H, Wagers A, Peters W, Charo I, Weissman IL, Cyster JG, Engleman EG. Nat Immunol. 2002; 3 (12): 1135-41
• Productive infection of plasmacytoid dendritic cells with human immunodeficiency virus type 1 is triggered by CD40 ligation. Fong L, Mengozzi M, Abbey NW, Herndier BG, Engleman EG. J Virol. 2002; 76 (21): 11033-41
• In vivo manipulation of dendritic cells to induce therapeutic immunity. Merad M, Sugie T, Engleman EG, Fong L. Blood. 2002; 99 (5): 1676-82
• Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R. Blood. 2002; 99 (5): 1517-26
• Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma. Davis TA, Hsu FJ, Caspar CB, van Beckhoven A, Czerwinsk DK, Liles TM, Taidi B, Benike CJ, Engleman EG, Levy R. Biol Blood Marrow Transplant. 2001; 7 (9): 517-22
• Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG. J Immunol. 2001; 167 (12): 7150-6
• Dendritic cell development from common myeloid progenitors. Manz MG, Traver D, Akashi K, Merad M, Miyamoto T, Engleman EG, Weissman IL. Ann N Y Acad Sci. 2001: 938 167-73; discussion 173-4
• Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Scappaticci FA, Smith R, Pathak A, Schloss D, Lum B, Cao Y, Johnson F, Engleman EG, Nolan GP. Mol Ther. 2001; 3 (2): 186-96
• Dendritic cells injected via different routes induce immunity in cancer patients. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. J Immunol. 2001; 166 (6): 4254-9
• Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG. Proc Natl Acad Sci U S A. 2001; 98 (15): 8809-14
• Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, Benike CJ, Reichardt V, van Beckhoven A, Rajapaksa R, Engleman EG, Blume KG, Levy R. Biol Blood Marrow Transplant. 2000; 6 (6): 621-7
• Dendritic cells in cancer immunotherapy. Fong L, Engleman EG. Annu Rev Immunol. 2000: 18 245-73
• Differentiation of myeloid dendritic cells into CD8alpha-positive dendritic cells in vivo. Merad M, Fong L, Bogenberger J, Engleman EG. Blood. 2000; 96 (5): 1865-72
• Development of CD8alpha-positive dendritic cells from a common myeloid progenitor. Traver D, Akashi K, Manz M, Merad M, Miyamoto T, Engleman EG, Weissman IL. Science. 2000; 290 (5499): 2152-4
• Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: studies of chimerism and anti-donor reactivity. Strober S, Benike C, Krishnaswamy S, Engleman EG, Grumet FC. Transplantation. 2000; 69 (8): 1549-54
• Comparison of primary sensitization of naive human T cells to varicella-zoster virus peptides by dendritic cells in vitro with responses elicited in vivo by varicella vaccination. Jenkins DE, Yasukawa LL, Bergen R, Benike C, Engleman EG, Arvin AM. J Immunol. 1999; 162 (1): 560-7
• Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Brockstedt DG, Podsakoff GM, Fong L, Kurtzman G, Mueller-Ruchholtz W, Engleman EG. Clin Immunol. 1999; 92 (1): 67-75
• Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study. Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R. Blood. 1999; 93 (7): 2411-9
• V7 (CD101) ligation inhibits TCR/CD3-induced IL-2 production by blocking Ca2+ flux and nuclear factor of activated T cell nuclear translocation. Soares LR, Tsavaler L, Rivas A, Engleman EG. J Immunol. 1998; 161 (1): 209-17
• Donor blood monocytes but not T or B cells facilitate long-term allograft survival after total lymphoid irradiation. Hayamizu K, Zeng D, Huie P, Garcia-Ojeda ME, Bloch DA, Fong L, Engleman EG, Sibley RK, Strober S. Transplantation. 1998; 66 (5): 585-93
• Isolation and utilization of human dendritic cells from peripheral blood to assay an in vitro primary immune response to varicella-zoster virus peptides. Jenkins DE, Yasukawa LL, Benike CJ, Engleman EG, Arvin AM. J Infect Dis. 1998: 178 Suppl 1 S39-42
• A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. Kundu SK, Engleman E, Benike C, Shapero MH, Dupuis M, van Schooten WC, Eibl M, Merigan TC. AIDS Res Hum Retroviruses. 1998; 14 (7): 551-60
• Dendritic cells: potential role in cancer therapy. Engleman EG, Cytotechnology. 1997; 25 (1-3): 1-8
• Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. J Immunol. 1997; 159 (7): 3113-7
• Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. Kim DT, Mitchell DJ, Brockstedt DG, Fong L, Nolan GP, Fathman CG, Engleman EG, Rothbard JB. J Immunol. 1997; 159 (4): 1666-8
• Ligation of the V7 molecule on T cells blocks anergy induction through a CD28-independent mechanism. Soares LR, Rivas A, Tsavaler L, Engleman EG. J Immunol. 1997; 159 (3): 1115-24
• Differential response of CD4+ V7+ and CD4+ V7- T cells to T cell receptor-dependent signals: CD4+ V7+ T cells are co-stimulation independent and anti-V7 antibody blocks the induction of anergy by bacterial superantigen. Soares LR, Rivas A, Ruegg C, Engleman EG. Eur J Immunol. 1997; 27 (6): 1413-21
• Allogeneic dendritic cell induction of HIV-specific cytotoxic T lymphocyte responses from T cells of HIV type 1-infected and uninfected individuals. Dupuis M, Peshwa MV, Benike C, Kundu SK, Engleman EG, Van Schooten WC, Merigan TC. AIDS Res Hum Retroviruses. 1997; 13 (1): 33-9
• Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Nat Med. 1996; 2 (1): 52-8
• Role of natural killer cells in the generation of influenza virus-specific cytotoxic T cells. Kos FJ, Engleman EG. Cell Immunol. 1996; 173 (1): 1-6
• Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Weinberg AD, Bourdette DN, Sullivan TJ, Lemon M, Wallin JJ, Maziarz R, Davey M, Palida F, Godfrey W, Engleman E, Fulton RJ, Offner H, Vandenbark AA. Nat Med. 1996; 2 (2): 183-9
• Immune regulation: a critical link between NK cells and CTLs. Kos FJ, Engleman EG. Immunol Today. 1996; 17 (4): 174-6
• Requirement for natural killer cells in the induction of cytotoxic T cells. Kos FJ, Engleman EG. J Immunol. 1995; 155 (2): 578-84
• Role of B70/B7-2 in CD4+ T-cell immune responses induced by dendritic cells. Fagnoni FF, Takamizawa M, Godfrey WR, Rivas A, Azuma M, Okumura K, Engleman EG. Immunology. 1995; 85 (3): 467-74
• Generation of antigen-specific CD4+ T cell lines from naive precursors. Mehta-Damani A, Markowicz S, Engleman EG. Eur J Immunol. 1995; 25 (5): 1206-11
• V7, a novel leukocyte surface protein that participates in T cell activation. II. Molecular cloning and characterization of the V7 gene. Ruegg CL, Rivas A, Madani ND, Zeitung J, Laus R, Engleman EG. J Immunol. 1995; 154 (9): 4434-43
• V7, a novel leukocyte surface protein that participates in T cell activation. I. Tissue distribution and functional studies. Rivas A, Ruegg CL, Zeitung J, Laus R, Warnke R, Benike C, Engleman EG. J Immunol. 1995; 154 (9): 4423-33
• Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. van Vollenhoven RF, Engleman EG, McGuire JL. Arthritis Rheum. 1995; 38 (12): 1826-31
• Prevention of AIDS transmission through screening of the blood supply. Galel SA, Lifson JD, Engleman EG. Annu Rev Immunol. 1995: 13 201-27
• Cellular and molecular basis of human gamma delta T cell activation. Role of accessory molecules in alloactivation. Takamizawa M, Fagnoni F, Mehta-Damani A, Rivas A, Engleman EG. J Clin Invest. 1995; 95 (1): 296-303
• Generation of antigen-specific CD8+ CTLs from naive precursors. Mehta-Damani A, Markowicz S, Engleman EG. J Immunol. 1994; 153 (3): 996-1003
• Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. Godfrey WR, Fagnoni FF, Harara MA, Buck D, Engleman EG. J Exp Med. 1994; 180 (2): 757-62
• An open study of dehydroepiandrosterone in systemic lupus erythematosus. van Vollenhoven RF, Engleman EG, McGuire JL. Arthritis Rheum. 1994; 37 (9): 1305-10
• Degradation of CD4 following phorbol-induced internalization in human T lymphocytes. Evidence for distinct endocytic routing of CD4 and CD3. Ruegg CL, Rajasekar S, Stein BS, Engleman EG. J Biol Chem. 1992; 267 (26): 18837-43
• Mechanism of HIV-1 entry into CD4+ T cells. Stein BS, Engleman EG. Adv Exp Med Biol. 1991: 300 71-86; discussion 87-96
• Early activation events render T cells susceptible to HIV-1-induced syncytia formation. Role of protein kinase C. Mohagheghpour N, Chakrabarti R, Stein BS, Gowda SD, Engleman EG. J Biol Chem. 1991; 266 (11): 7233-8
• Evidence for the involvement of CD56 molecules in alloantigen-specific recognition by human natural killer cells. Suzuki N, Suzuki T, Engleman EG. J Exp Med. 1991; 173 (6): 1451-61
• Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells. Suzuki T, Suzuki N, Daynes RA, Engleman EG. Clin Immunol Immunopathol. 1991; 61 (2 Pt 1): 202-11
• Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation. Chakrabarti R, Engleman EG. J Biol Chem. 1991; 266 (19): 12216-22
• Alloantigen-specific cytotoxic clones bearing the alpha,beta T cell antigen receptor but not CD4 or CD8 molecules. Rivas A, Koide J, Laus R, Engleman EG. J Immunol. 1990; 145 (2): 470-6
• Anti-DNA antibody production by CD5+ and CD5- B cells of patients with systemic lupus erythematosus. Suzuki N, Sakane T, Engleman EG. J Clin Invest. 1990; 85 (1): 238-47
• Differences in surface phenotype and mechanism of action between alloantigen-specific CD8+ cytotoxic and suppressor T cell clones. Koide J, Engleman EG. J Immunol. 1990; 144 (1): 32-40
• Natural killer lines and clones with apparent antigen specificity. Suzuki N, Bianchi E, Bass H, Suzuki T, Bender J, Pardi R, Brenner CA, Larrick JW, Engleman EG. J Exp Med. 1990; 172 (2): 457-62
• Impaired immunity in AIDS. The mechanisms responsible and their potential reversal by antiviral therapy. Ruegg CL, Engleman EG. Ann N Y Acad Sci. 1990: 616 307-17
• Intracellular processing of the gp160 HIV-1 envelope precursor. Endoproteolytic cleavage occurs in a cis or medial compartment of the Golgi complex. Stein BS, Engleman EG. J Biol Chem. 1990; 265 (5): 2640-9
• Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. Markowicz S, Engleman EG. J Clin Invest. 1990; 85 (3): 955-61
• Identification of an immunostimulating protein from Mycobacterium leprae. Mohagheghpour N, Munn MW, Gelber RH, Engleman EG. Infect Immun. 1990; 58 (3): 703-10
• Evidence that T cell activation is required for HIV-1 entry in CD4+ lymphocytes. Gowda SD, Stein BS, Mohagheghpour N, Benike CJ, Engleman EG. J Immunol. 1989; 142 (3): 773-80
• Expression and processing of human immunodeficiency virus type 1 gag and pol genes by cells infected with a recombinant vaccinia virus. Gowda SD, Stein BS, Steimer KS, Engleman EG. J Virol. 1989; 63 (3): 1451-4
• Evidence for involvement of the gamma, delta T cell antigen receptor in cytotoxicity mediated by human alloantigen-specific T cell clones. Rivas A, Koide J, Cleary ML, Engleman EG. J Immunol. 1989; 142 (6): 1840-6
• Identification of protein intermediates in the processing of the p55 HIV-1 gag precursor in cells infected with recombinant vaccinia virus. Gowda SD, Stein BS, Engleman EG. J Biol Chem. 1989; 264 (15): 8459-62
• Evidence that cytotoxic lymphocytes alter and traverse allogeneic endothelial cell monolayers. Bender JR, Pardi R, Kosek J, Engleman EG. Transplantation. 1989; 47 (6): 1047-53
• Natural killer (NK)-like cytotoxic activity of allospecific T cell receptor-gamma,delta+ T cell clones. Distinct receptor-ligand interactions mediate NK-like and allospecific cytotoxicity. Koide J, Rivas A, Engleman EG. J Immunol. 1989; 142 (12): 4161-8
• Acquired immune tolerance to cadaveric renal allografts. A study of three patients treated with total lymphoid irradiation. Strober S, Dhillon M, Schubert M, Holm B, Engleman E, Benike C, Hoppe R, Sibley R, Myburgh JA, Collins G. N Engl J Med. 1989; 321 (1): 28-33
• A subset of human rosetted lymphocytes contains previously unidentified histamine. Khan MM, Fishwild DM, Melmon KL, Coutre S, Engleman EG, Bauer JA. Clin Immunol Immunopathol. 1989; 52 (2): 147-59
• Differences in surface phenotype between cytolytic and non-cytolytic CD4+ T cells. MHC class II-specific cytotoxic T lymphocytes lack Leu 8 antigen and express CD2 in high density. Takada S, Koide J, Engleman EG. J Immunol. 1989; 142 (9): 3038-44
• Activation of HLA-restricted EBV-specific cytotoxic T cells does not require CD4+ (helper) T cells or exogenous cytokines. Fishwild DM, Benike CJ, Engleman EG. J Immunol. 1988; 140 (6): 1994-8
• Clinical and immunological studies of cadaveric renal transplant recipients given total-lymphoid irradiation and maintained on low-dose prednisone. Saper V, Chow D, Engleman ED, Hoppe RT, Levin B, Collins G, Strober S. Transplantation. 1988; 45 (3): 540-6
• Human T cell leukemia virus-I-associated T-suppressor cell inhibition of erythropoiesis in a patient with pure red cell aplasia and chronic T gamma-lymphoproliferative disease. Levitt LJ, Reyes GR, Moonka DK, Bensch K, Miller RA, Engleman EG. J Clin Invest. 1988; 81 (2): 538-48
• CD4 molecules are associated with the antigen receptor complex on activated but not resting T cells. Rivas A, Takada S, Koide J, Sonderstrup-McDevitt G, Engleman EG. J Immunol. 1988; 140 (9): 2912-8
• T cell regulatory disturbances in the rheumatic diseases. Alpert SD, Koide J, Takada S, Engleman EG. Rheum Dis Clin North Am. 1987; 13 (3): 431-45
• Evidence for an association between CD8 molecules and the T cell receptor complex on cytotoxic T cells. Takada S, Engleman EG. J Immunol. 1987; 139 (10): 3231-5
• Lymphocyte subsets differentially induce class II human leukocyte antigens on allogeneic microvascular endothelial cells. Pardi R, Bender JR, Engleman EG. J Immunol. 1987; 139 (8): 2585-92
• Human monoclonal antibodies to Rh0(D). Foung SK, Blunt JA, Wu PS, Ahearn P, Winn LC, Engleman EG, Grumet FC. Vox Sang. 1987; 53 (1): 44-7